Septerna
SEPN
36.00
+0.33
+0.93%
Septerna
US · SEPN
#2886 by market cap
Listed 2024
36.00
+0.33
+0.93%
Live - 5344 symbols - heartbeat 477s ago
· 2026-10-08 07:18
Pre-market
36.00
0.00%
After-hours
36.00
0.00%
- Market cap
- 1.68B
- P/E (TTM)i
- -67.92
- P/Bi
- 4.35
- EPSi
- -1.10
- Div yieldi
- 0.00%
- 52W posi
- 55%
Reader sentiment
Are you bullish or bearish on SEPN?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions increased by 1 in the most recent period (2026/Q3).
- Total institutional ownership fell 6.0 percentage points.
Institutional ownership
- Held by institutions
- 99.03% -5.95pp
- Institutions
- 193 +1
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
VC/PE Fund47.48%
Mutual Fund37.64%
Hedge Fund9.04%
Public Company4.30%
Individual/Insider2.86%
Private Company0.35%
Government Pension Fund0.17%
Top holders as of 2026-08-12
Third Rock Ventures, LLC
22.02% · 10.28M sh
RA Capital Management, L.P.
11.79% · 5.50M sh
Driehaus Capital Management LLC
9.50% · 4.43M sh
Samsara BioCapital LLC
6.75% · 3.15M sh
BlackRock
4.14% · 1.93M sh
Artal Group S.A.
4.07% · 1.90M sh
The Goldman Sachs Group, Inc.
3.68% · 1.72M sh
Vanguard Capital Management, LLC
2.97% · 1.39M sh
Goldman Sachs Asset Management, L.P.
2.88% · 1.34M sh
Avoro Capital Advisors LLC
2.87% · 1.34M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 32 buys · 18 sells
| Name | Role | Stake |
|---|---|---|
| Third Rock Ventures, LLC | -- | 22.02% |
| RA Capital Management, L.P. | -- | 11.79% |
| Jeffrey Finer | Chief Executive Officer | 1.66% |
| Elizabeth Bhatt | Chief Operating Officer | 0.37% |
| Uwe Klein | Senior Vice President of Biological Sciences | 0.27% |
| R. Alan Ezekowitz | Director | 0.25% |
| Daniel Long | Senior Vice President of Drug Discovery | 0.21% |
| Gilbert Labrucherie | Chief Financial Officer | 0.09% |
| Samira Shaikhly | Chief Human Resources Officer | 0.00% |
| Shalini Sharp | Independent Director | -- |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Daniel Long | Senior Vice President of Drug Discovery | Intent to Sell (Form 144) | -10,001 | $39.13 |
| 2026-09-30 | Samira Shaikhly | Chief Human Resources Officer | Intent to Sell (Form 144) | -12,592 | $39.13 |
| 2026-09-07 | Rajiv Patni | Chief Medical Officer | Other Derivative Acquisition | +275,000 | $37.37 |
| 2026-08-31 | Daniel Long | Senior Vice President of Drug Discovery | Derivative Exercise and Sale | -3,333 | $2.76–37.83 |
| 2026-08-11 | RA Capital Management, L.P. | -- | Private Disposition | -1,493,000 | $42.50 |
| 2026-08-11 | Third Rock Ventures, LLC | -- | Automatic Disposition | -147,200 | $50.27–51.08 |
| 2026-08-10 | Elizabeth Bhatt | Chief Operating Officer | Derivative Exercise and Sale | -25,000 | $2.76–44.00 |
| 2026-08-02 | Daniel Long | Senior Vice President of Drug Discovery | Derivative Exercise and Sale | -3,334 | $2.76–34.68 |
| 2026-07-14 | Elizabeth Bhatt | Chief Operating Officer | Derivative Exercise and Sale | -4,000 | $6.81–33.99 |
| 2026-06-30 | Daniel Long | Senior Vice President of Drug Discovery | Derivative Exercise and Sale | -3,333 | $2.76–34.81 |
| 2026-06-28 | Samira Shaikhly | Chief Human Resources Officer | Derivative Exercise and Sale | -2,178 | $6.81–35.18 |
| 2026-06-25 | R. Alan Ezekowitz | Director | Other Derivative Acquisition | +15,000 | $37.34 |
| 2026-06-25 | RA Capital Management, L.P. | -- | Other Derivative Acquisition | +15,000 | $37.34 |
| 2026-06-25 | Shalini Sharp | Independent Director | Other Derivative Acquisition | +15,000 | $37.34 |
| 2026-06-25 | Jeffrey Tong | Chairperson | Other Derivative Acquisition | +15,000 | $37.34 |
| 2026-06-25 | Bernard Coulie | Independent Director | Other Derivative Acquisition | +15,000 | $37.34 |
| 2026-06-25 | Keith Gottesdiener | Director | Other Derivative Acquisition | +11,260 | $37.34 |
| 2026-06-25 | Jake Simson | Independent Director | Other Derivative Acquisition | +15,000 | $37.34 |
| 2026-06-25 | Abraham Bassan | Independent Director | Other Derivative Acquisition | +15,000 | $37.34 |
| 2026-06-21 | Daniel Long | Senior Vice President of Drug Discovery | Derivative Exercise and Sale | -15,000 | $2.76–35.97 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:18:22 · For reference only, not investment advice and not tailored to your situation.